Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 3, 2004 - Issue 3
Submit an article Journal homepage
134
Views
19
CrossRef citations to date
0
Altmetric
Review

Risk–benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting

Jørn Herrstedt Jørn Herrstedt MD Department of Oncology RA 54 B1, Copenhagen University Hospital, DK-2730 Herlev, Denmark. [email protected]
Pages 231-248 | Published online: 03 Mar 2005

Bibliography

  • MORROW GR: The assessment of nausea and vomiting: past problems, current issues, and suggestions for future research. Cancer (1984) 53\(Suppl. 10):2267–2278.
  • COATES A, ABRAHAM S, KAYE SB et al: On the receiving end - patient perception of the side-effects of cancer chemotherapy. Ear: J. Cancer Clin. Oncol (1983) 19:203–208.
  • GRALLA RJ, ITRI L, PISKO S et al.: Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced vomiting. N. Engl. I. Med. (1981) 305:905–909.
  • MARTIN M, DIAZ-RUBIO E, SANCHEZ A, ALMENAREZ J, LOPEZ-VEGA M: The natural course of emesis after carboplatin treatment. Acta Oncol (1990) 29:593–595.
  • HERRSTEDT J, AAPRO MS, SMYTH JF, DEL FAVERO A: Corticosteroids, dopamine antagonists and other drugs. Support. Care Cancer (1998) 6:204–214.
  • HESKETH PJ, KRIS MG, GRUNBERG SM et al: Proposal for classifying the acute emetogenicity of cancer chemotherapy. Clin. Oncol (1997) 15:103–109.
  • DE BOER-DENNERT M, DE WIT R, SCHMITZ PIM et al: Patient perceptions of the side-effects of chemotherapy: the influence of 5-HT3 antagonists. Br. J. Cancer (1997) 76:1055–1061.
  • PEROUTKA SJ: Chemotherapeutic agents do not interact with neurotransmitter receptors. Cancer Cheinother. Pharinacol (1987) 19:131–132.
  • HERRSTEDT J, HYTTEL J, PEDERSEN J: Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine HI, muscarine cholinergic and aradrenergic receptors. Cancer Cheinother. Pharinacol (1993) 33:53–56.
  • THUMAS LJ: Ober das Brechcentrum und über die Wirkung einiger pharmakologischer Mittel auf dasselbe. Archieves für Patologische Anatomic. (1891) 123:44–69.
  • HATCHER RA, WEISS S: Studies on vomiting. Pharinacol Exp. The]: (1923) 22:139–193.
  • WANG SC, BORISON HL: A new concept of organization of the central emetic mechanism: recent studies on sites of action of apomorphine, copper sulphate and cardiac glycosides. Gastroenterology(1952) 22:1–12.
  • BORISON HL, WANG SC: Physiology and pharmacology of vomiting. Pharinacol Rev (1953) 5:193–230.
  • WALSH D, NELSON KA, MAHMOUD FA: Established and potential therapeutic applications of cannabinoids in oncology. Support. Care Cancer (2003) 11:137–143.
  • GADDUM JH, PICARELLI ZP: Two kinds of tryptamine receptor. Br. Pharinacol Cheinother. (1957) 12:323–328.
  • BRADLEY PB, ENGEL G, FENIUK W et al.: Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharinacology (1986) 25(6):563–576.
  • HOYER D, CLARKE DE, FOZARD JR et al.: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharinacol Rev (1994) 46:157–203.
  • VON EULER VS, GADDUM JH: An unidentified depressor substance in certain tissue extracts. Physiol (Lmid) (1931) 72:577–583.
  • CHANG M, LEEMAN SE: Isolation of sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J. Biol Chem. (1970) 245:4784–4790.
  • LEROY V, MAUSER P, GAO Z, PEET NP:Neurokinin receptor antagonists. Expert Opin. Investig. Drugs (2000) 9:735–746.
  • MATSUMOTO M, YOSHIOKA M, TOGASHI H, TOCHIHARA M, IKEDA T, SAITO H: Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. Pharmacol Exp. The]: (1995) 272:1044–1051.
  • ZARPE A, ARTAIZ I, DEL RIO J: Role of 5-HT3 receptors in basal and K.'-evoked dopamine release from rat olfactory tubercle and striatal slices. Br: J. Pharmacol (1994) 113:968–972.
  • BRUERA E, CASTRO M: Cannabinoids insupportive care: are they necessary? Support. Care Cancer (2003) 11:133–134.
  • JOVANOVIC-MICIC D, SAMARDZIC R, BELESLIN DB: The role of a-adrenergic mechanisms within the area postrema in dopamine-induced emesis. Eur.j Pharmacol (1995) 272:21–30.
  • GODLEWSKI G, GOTHERT M, MALINOWSKA B: Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex. Br. Pharmacol (2003) 138:767–774.
  • ISON PJ, PEROUTKA SJ: Neuroreceptor binding studies predict antiemetic effect and side effects. Cancer Treat. Rep. (1986) 70:637–641.
  • MINER WD, SANGER GJ: Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br. J. Pharmacol (1986) 88:497–499.
  • VAN WIJNGAARDEN I, TULP MT, SOUDIJN W: The concept of selectivity in 5-HT receptor research. Ear: Pharmacol (1990) 188:301–312.
  • SNIDER RM, CONSTANTINE JW, LOWE JA III et al.: A potent nonpeptide antagonist of the substance P (NKI) receptor. Science (1991) 251:435–437.
  • DIEMUNSCH P, GRELOT P: Potential of substance P receptor antagonists as antiemetics. Drugs (2000) 60:533–546.
  • HERRSTEDT J, SIGSGAARD T, HANDBERG J et al: Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during cisplatinum-based chemotherapy in patients with cancer. J. Clin. Oncol (1997) 15:1690–1696.
  • HESKETH PJ, VAN BELLE S, AAPRO MS et al: Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur. J. Cancer (2003) 39:1074–1080.
  • HARGREAVES R: Imaging substance P receptors (NKI) in the living human brain using positron emission tomography. Clin. Psychiatry (2002) 63\(Suppl. 11):18–24.
  • WILCOX PM, FETTING JH, NETTESHEIM KM, ABELOFF MD: Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) adjuvant chemotherapy for breast cancer. Cancer Treat. Rep. (1982) 66:1601–1604.
  • LEIBUNDGUT U, LANCRANJAN I: First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet (1987) 1:1198.
  • CUNNINGHAM D, HAWTHORN J, POPLE A et al.: Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 1:1461–1462.
  • THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann. Oncol (1995) 6:805–810.
  • MARTY M, POUILLART P, SCHOLL S et al.: Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl. J. Med. (1990) 322:816–821.
  • WARR D, WILAN A, VENNER P et al.: A randomized, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial. Ear. J. Cancer (1992) 29A:33–36.
  • SORBE B, HOGBERG T, GLIMELIUS B et al.: A randomized, multicenter study comparing efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer (1994) 73:445–454.
  • CHEVALLIER B, CAPPELAERE P, SPLINTER T et al.: A double-blind, multicenter comparison of intravenous dolasetron mesylate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support. Care Cancer (1997) 5:22–30.
  • HESKETH PJ, NAVARI R, GROTE T et al.: Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J. Clin. Oncol (1996) 14:2242–2249.
  • AUDHUY B, CAPPELAERE P, MARTIN M et al.: A double-blind, randomized comparison of the anti-emetic effect of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin-based chemotherapy. Eur. J. Cancer (1996) 32A:807–813.
  • BONNETERRE J, CHEVALLIER B, METZ R et al.: A randomized, double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. Clin. Oncol (1990) 8:1063–1069.
  • KAASA S, KVALOY S, DICATO MA et al.: A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Ear. J. Cancer (1990) 26:311–314.
  • JONES AL, HILL AS, SOUKOP M et al.: Comparison of ondansetron and dexamethasone in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 338:483–487.
  • FAUSER A, BLEIBERG H, CHEVALLIER B et al.: A double-blind, randomized parallel study of iv dolasetron mesilate versus iv metoclopramide in patients receiving moderately emetogenic chemotherapy. Cancer (1996) 9:196–202.
  • WARR D, WILLAN A, FINES et al: Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J. Natl. Cancer Inst. (1991) 83:1169–1173.
  • ANDERSON H, THATCHER N, HOWELL A et al.: Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting. Ear: J. Cancer (1994) 30A:610–615.
  • KRIS MG, GRALLA RJ, CLARK RA et al:Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. Clin. Oncol (1985) 3:1379–1384.
  • NAVARI RM, MADAJEWICZ S, ANDERSON N et al.: Oral ondansetron for the control of cisplatin-induced delayed emesis: a large multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. Clin. Oncol (1995) 13:2408–2416.
  • OLVER I, PASKA W, DEPIERRE A et al: A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann. Oncol (1996) 7:945–952.
  • LATREILLE J, PATER J, JOHNSTON D et al: Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. Clin. Oncol (1998) 16:1174–1178.
  • GOEDHALS L, HERON JF, KLEISBAUER JP, PAGANI O, SESSA C: Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann. Oncol (1998) 9:661–666.
  • THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. Clin. OncoL (1997) 15:124–130.
  • PATER JL, LOFTERS WS, ZEE B et al:The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann. Oncol (1997) 8:181–185.
  • KAIZER L, WARR D, HOSKINS P et al:Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a Phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol (1994) 12:1050–1057.
  • THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl. J. Med. (2000) 342:1554–1559.
  • •Randomised, double-blind study in patients receiving moderately emetogenic chemotherapy. In patients without acute emesis, dexamethasone was as effective as dexamethasone plus ondansetron in the protection against delayed emesis.
  • BAKER JJ, LOCKEY JL, PRICE NA, WINOKUR SH, BOWEN J: Nabilone as an antiemetic. N. Engl. J. Med. (1979) 301:728.
  • AAPRO MS: Corticosteroids as antiemetics. In: Recent Results In Cancer Research. Senn HJ, Glaus A, Schmid L (Eds), Springer-Verlag, Berlin Heidelberg (1988) 108:102–111.
  • D'OLIMPIO JT, CAMACHO F, CHANDRA P et al.: Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy: a randomised, double-blind, controlled clinical trial. J. Clin. Oncol. (1985) 3:1133–1135.
  • THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin acute emesis. Clin. Oncol. (1998) 16:2937–2948.
  • •Randomised, double-blind study defming the optimal dose of dexamethasone in prevention of acute cisplatin-induced emesis.
  • THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Randomized, double-blind, dose-finding study of dexamethasone in prevention of acute emesis induced by anthracyclines, carboplatin and cyclophosphamide. Clin. Oncol. (2004) 22:725–729.
  • •Randomised, double-blind study defming the optimal dose of dexamethasone in prevention of acute emesis induced by moderately emetogenic chemotherapy.
  • ALLAN SG, CORNBLEET MA, WARRINGTON PS, GOLLAND IM, LEONARD RC, SMYTH JF: Dexamethasone and high-dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. Br. Med. J. (1984) 289:878–879.
  • ROILA F, TONATO M, COGNETTI F et al.: Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.Oncol. (1991)9:675–678.
  • HERON JF, GOEDHALS L, JORDAAN JP, CUNNINGHAM J, CEDAR E: Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann. Oncol. (1994) 5:579–584.
  • SORBE B, HOGBERG T, HIMMELMANN A et al.: Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy. Ear: J. Cancer (1994) 30A:629–634.
  • ANTIEMETIC SUBCOMMITTEE OF THE MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER (MASCC): Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann. Oncol. (1998) 9:811–819.
  • ••Evidence-based antiemetic guidelinesrecommended by the Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCO.
  • THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl. J. Med. (1995) 332:1–5.
  • KRIS MG, GRALLA RJ, TYSON LB, CLARK RA, CIRRINCIONE C, GROSHEN S: Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. Clin. Oncol. (1989) 7:108–114.
  • THE ITALIAN MULTICENTER STUDY GROUP: A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. Anticancer Drugs (1999) 10:465–470.
  • PINDER RIVI, BROGDEN RN, SAWYER PR, SPEIGHT TM, AVERY GS: Metoclopramide: a review of its pharmacological and clinical use. Drugs (1976) 12:81–131.
  • LEBEAU B, DEPIERRE A, GIOVANNI M et al.: The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. Ann. Oncol. (1997) 8:887–892.
  • HERRSTEDT J, SIGSGAARD T, BOESGAARD M, JENSEN TP, DOMBERNOWSKY P: Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl. J. Med. (1993) 328:1076–1080.
  • LEE CW, SUH CW, LEE JS et al.: Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis. I Korean Med. Sci. (1994) 9:369–375.
  • SALLAN SE, CRONIN C, ZELEN M, ZINBERG NE: Antiemetics in patients receiving chemotherapy for cancer. A randomised comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl. I Med. (1980) 302:135–138.
  • ORR LE, MCKERMAN JF, BLOOME B: Antiemetic effect of tetrahydrocannabinol compared with placebo and prochlorperazine in chemotherapy-associated nausea and vomiting. Arch. Intern. Med. (1980) 140:1431–1433.
  • CUNNINGHAM D, BRADLEY CJ, FORREST GJ et al.: A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Ear: J. Cancer Clin. Oncol. (1988) 24:685–689.
  • BRUERA E, CASTRO M: Cannabinoids in supportive care: are they necessary? Support. Care Cancer (2003) 11:133–134.
  • KRIS MG, RADFORD JE, PIZZO BA, INABINET R, HESKETH A, HESKETH PJ: Use of an NKI receptor antagonist to prevent delayed emesis after cisplatin. Natl. Cancer Inst. (1987) 89:817–818.
  • HESKETH PJ, GRALLA RJ WEBB RT et al: Randomized Phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J. Clin. Oncol. (1999) 17:338–343.
  • COCQUYT V, VAN BELLES, REINHARDT RR et al: Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur. J. Cancer (2001) 37:835–842.
  • NAVARI RM, REINHARDT RR, GRALLA RJ et al: Reduction of cisplatin-induced emesis by a selective neurokinin- 1-receptor antagonist. N Engl. J. Med. (1999) 340:190–195.
  • VAN BELLE S, LICHINITSER MR, NAVARI RM et al.: Prevention of cisplatin-induced acute and delayed emesis by selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer (2002) 94:3032–3041.
  • CAMPOS D, RODRIGUES-PEREIRA J,REINHARDT RR et al.: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Chia. Oncol (2001) 19:1759–1767.
  • CHAWLA SP, GRUNBERG SM, GRALLA RI et al: Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer (2003) 97:2290–3000.
  • POLI-BIGELLI S, RODRIGUES-PEREIRA J, CARIDES AD et al.: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer (2003) 97:3090–3098.
  • ••Randomised, double-blind Phase III studyshowing that aprepitant, the first drug in a new class of antiemetics, the NKI receptor antagonist, improves the effect of standard antiemetic therapy in patients receiving cisplatin-based chemotherapy.
  • HESKETH PJ, GRUNBERG SM, GRALLA RI et al; APREPITANT PROTOCOL 052 STUDY GROUP: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. Chia. Omni (2003) 21:4112–4119.
  • ••Randomised, double-blind Phase III studyshowing that aprepitant, the first drug in a new class of antiemetics, the NKI receptor antagonists, improves the effect of standard antiemetic therapy in patients receiving cisplatin-based chemotherapy.
  • KRIS MG, GRALLA RI, CLARK RA, TYSON LB, GROSHEN S: Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. Cancer (1987) 60:2816–2822.
  • HERRSTEDT J, HANNIBAL J, HALLAS J, ANDERSEN E, LAUERSEN LC, HANSEN M: High-dose metoclopramide + lorazepam versus low dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting. Ann. Oncol (1991) 2:223–227.
  • GREENBERG DB, SURMAN OS, CLARKE J, BAER L: Alprazolam for phobic nausea and vomiting related to cancer chemotherapy. Cancer Treat. Rep. (1987) 71:549–560.
  • WATTERS JW, MCLEOD HL: Cancer pharmacogenomics: current and future applications. Biochim. Biophys. Acta (2003) 1603:99–111.
  • SPARREBOOM A, DANESI R, ANDO Y, CHAN J, FIGG WD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. (2003) 6:71–84.
  • NICHOLIS H: Improving drug response with pharmacogenomics. Drug Discov. Today (2003) 8:281–282.
  • GURUBHAGAVALUTA S, LIU G, PARKS et al: XPD and XRCC1 genetic polymorphisms are associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with platinum chemotherapy. Proc. Am. Soc. Chia. Oncol (2003) 22:123. Abstract 491.
  • INNOCENTI F, UNDEVIA SD, IYER L et al: Genetic variants in the UDP-glucoronosyltransferase 11 gene predict the risk of severe neutropenia of irinotecan. Chia. Omni (2004). Published online March 8.
  • LEE CR, PLOSKER GL, MCTAVISH D: Tropisetron. A review of its pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs (1993) 46:925–943.
  • KAISER R, SEZER O, PAPIES A et al.: Patient-tailored antiemetic treatment with 5-hydroxytryptamine Type 3 receptor antagonists according to cytochrome P450 2D6 genotypes. J. Chia. Oncol (2002) 20:2805–2811.
  • ••Interesting study showing that thegenotype of the cytochrome CYP2D6 can influence the antiemetic protection of 5-HT3 receptor antagonists.
  • ASHFORTH El, PALMER IL, BYE A, BEDDING A: The pharmacoldnetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br. J. Clin. Pharmacol (1994) 37:389–391.
  • JONES GR: Cancer therapy: phenothiazines in an unexpected role. Tumori (1985) 71:563–569.
  • RAMU A, RAMU N: Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemothec Pharmacol (1992) 30:165–173.
  • SRIDHAR KS, KRISHAN A, SAMY TS et al.: Prochlorperazine as a doxorubicin-efflux blocker: Phase I clinical trial and pharmacokinetic studies. Cancer Chemother. Pharmacol (1993) 31:423–430.
  • KJELLEN E, WENNERBERG J, PERO R: Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck. Br. J. Cancer (1989) 59:247–250.
  • POLLERA CE COGNETTI F, NARDI M, MAZZA D: Sudden death after dystonic reaction to high-dose metoclopramide. Lancet (1984) 2:460–461.
  • MURRAY GB, GREENBERG DB: Respiratory dyskinesia associated with hexamethylmelamine. Cancer Treat. Rep. (1980) 64:355–356.
  • HAID M: Steroid antiemesis may be harmful. N. Engl. J. Med. (1981) 304:1237.
  • MARINI G, MURRAY S, GOLDHIRSCH A: The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. Ann. Oncol (1996) 7:245–250.
  • POWELL BC, MUTCH DG, KAO MS et al.: Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic (NC) cell activity. Cancer (1990) 65:466–472.
  • AAPRO MS, ALBERTS DS, SEROKMAN R: Lack of dexamethasone effect on the tumor activity of cisplatin. Cancer Treat. Rep. (1983) 67:1013–1017.
  • BLOOMER IC, BALDWIN SJ, SMITH GI, AYRTON AD, CLARKE SE, CHENERY RJ: Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br. J. Chia. Pharmacol (1994) 38:557–566.
  • FIRKUSNY L, KROEMER HK, EICHELBAUM M: Characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron: a molecular base for interindividual variability and interaction potential. Biochem. Pharmacol (1995) 49:1777–1784.
  • FISCHER V, VICKERS AEM, HEITZ S et al.: The polymorphic cytochrome P4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metal,. Dispos. (1994) 22:269–274.
  • SANWALD P, DAVID M, DOW J: Characterization of the cytochrome P450 enzymes involved in the M vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metal,. Dispos. (1996) 24:602–609.
  • DIXON CM, COLTHUP PV, SERABJIT-SINGH CJ et al.: Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metal,. Dispos. (1995) 23:1225–1230.
  • WATANABE Y, NAKAJIMA H, NOZAKI K, HOSHIAI H, NODA K: The effect of granisetron on M vitro metabolism of paclitaxel and docetaxel. Cancer (2003) 9:67–70.
  • GODDARD PM, JONES M, POLLARD LA et al: The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice. Cancer Chemother. Pharmacol (1990) 25:377–379.
  • HALL TJ, CAMBRIDGE G, JAMES PR: Development of a co-culture system with induced HEPG2 cells and K562 cells for examining drug metabolism M vitro. Studies with cyclophosphamide, ondansetron and cisplatin. Res. Commun. Chem. Pathol Pharmacol (1991) 72:161–168.
  • CAGNONI PJ, MATTHES S, DAY TC, BEARMAN SI, SHPALL EJ, JONES RB: Modification of the pharmacolkinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant. (1999) 24:1–4.
  • GILBERT CJ, PETROS WP, VREDENBURGH J et al.: Pharmacolkinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother. Pharmacol (1998) 42:497–503.
  • LORENZ C, EICKHOFF C, BAUMANN F et al.: Does ondansetron affect the metabolism of cyclophosphamide? Int. J. Clin. Pharmacol Ther. (2000) 38:143–144.
  • LAZARUS HM, BRYSON JC, LEMON E, PRITCHARD JF, BLUMER J: Antiemetic efficacy and pharmacolkinetic analyses of the serotonin antagonist ondansetron (GR 38032F) during multiple-day chemotherapy with cisplatin prior to autologous bone marrow transplantation. Natl. Cancer Inst. (1990) 82:1776–1778.
  • BLUM RA, MAJUMDAR A, MCCREA J et al.: Effects of aprepitant on the pharmacolkinetics of ondansetron and granisetron in healthy subjects. Clin. Ther. (2003) 25:1407–1419.
  • DE BRUIJN K: Tropisetron. A review of the clinical experience. Drugs (1992) 43 (Suppl. 3):11–22.
  • KORTECH OM: Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients. Clin. Oncol (1995) 7:371–372.
  • OREN DA: Dysphoria after treatment with ondansetron. Am." Psychiatry (1995) 152:1101.
  • DIMMITT DC, CRAMER MB, KEUNG A, ARUMUGHAM T, WEIR SJ: Pharmacolkinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. Cancer Chemother. Pharmacol (1999) 43:126–132.
  • DUHEM C, RIES F, DICATO M: Side-effects of antiemetics. In: Medical Management of Cancer Treatment Induced Emesis Dicato M (Ed.), Martin Dunitz, London (1998):221–228.
  • HERRSTEDT J, JEPPESEN BH, DOMBERNOWSKY P: Dose-limiting hypotension with the 5-HT3-antagonist batanopride (BMY-25801). Ann. Oncol (1991) 2:154–155.
  • BLOWER PR: Granisetron: relating pharmacology to clinical effect. Support. Care Cancer (2003) 11:93–100.
  • GRALLA RJ, OSOBA D, KRIS MG et al: Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J. Clin. Oncol (1999) 17:2971–2994.
  • ••Evidence-based antiemetic guidelinesrecommended by the American Society for Clinical Oncology (ASCO).
  • MOERTEL CG, REITEMEIER RJ: Controlled clinical studies of orally administered antiemetic drugs. Gastroenterology (1969) 57:262–268.
  • MORRAN C, SMITH DC, ANDERSON DA, MCARDLE CS: Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. Br. Med. J. (1979) 287:1323–1324.
  • GRUNBERG SM, EHLER E, MCDERMED JE, AKERLEY WL: Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. Natl. Cancer Inst. (1988) 80:864–868.
  • DEVINE ML, DOW GJ, GREENBERG BR et al.: Adverse reactions to delta-9-tetrahydrocannabinoid given as an antiemetic in a multicenter study. Clin. Pharm. (1987) 6:319–322.
  • BEAL JE, OLSON R, LAUBENSTEIN L et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. I. Pain Symptom Manage. (1995) 10:89–97.
  • OSOBA D, WARR DG, FITCH MI, NAKASHIMA L, WARREN B: Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: a consensus. Can. J. Oncol (1995) 5:381–400.
  • ASHP COMMISION ON THERAPEUTICS: ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am. J. Health Syst. Pharm. (1999) 56:729–764.
  • ESMO GUIDELINES TASK FORCE: ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann. Oncol (2001) 12:1059–1060.
  • THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann. Oncol (1998) 9:759–765.
  • DE ANGELIS V, ROILA F, SABBATINI R et al: Cancer chemotherapy (CT)-induced delayed emesis: antiemetic prescriptions in clinical practice. Proc. Am. Soc. Gin. Oncol (2003) 22:739. Abstract 2971.
  • DEMOOR C, COHEN L, EISENBERG PD, GRUNBERG SM, KIM YJ, RUBENSTEIN ER: Oncologists' compliance with antiemetic guidelines (AEG) and outcomes of patients (pts) receiving emetogenic chemotherapy (CT). Proc. Am. Soc. Clio. Oncol (2003) 22:727. Abstract 2924.
  • LADEWSKI LA, BELKNAP SM, NEBEKER JR et al.: Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J. Chit. Oncol (2003) 21:3859–3866.
  • GRUNBERG SM, DEUSON RR, MAVROS P et at.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer (2004). In Press.
  • ROSCOE JA, MORROW GR, HICKOK JT, STERN RIVI: Nausea and vomiting remain a significant clinical problem. Trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. Paul Symptom Manage. (2000) 20:113–121.
  • GRIFFIN AM, BUTOW PN, COATES AS et al.: On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann. Oncol (1996) 7:189–195.
  • GRALLA RJ, LICHINITSER M, VAN DER VEGT S et al.: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol (2003) 14:1570–1577.
  • •Randomised, double-blind study comparing a new 5-HT3 receptor antagonist, palonosetron, with ondansetron in patients receiving moderately emetogenic chemotherapy.
  • EISENBERG P, FIGUEROA-VADILLO J, ZAMORA R et al: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer (2003) 98:2473–2482.
  • •Randomised, double-blind study comparing a new 5-HT3 receptor antagonist, palonosetron, with dolasetron in patients receiving moderately emetogenic chemotherapy.
  • SIGSGAARD TC, HERRSTEDT J, HANDBERG J, KJ/ER M, DOMBERNOWSKY P: Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J. Chit. Oncol (2001) 19:2091–2097.
  • •Randomised, double-blind study in patients receiving multiple cycles of moderately emetogenic chemotherapy. The antiemetic effect of ondansetron plus metopimazine plus prednisolone was superior to ondansetron plus metopimazine, but none of the treatments were able to maintain efficacy through multiple cycles.
  • DE WIT R, VAN DEN BERG H, BURGHOUTS J et al: Initial high antiemetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br. J. Cancer (1998) 77:1487–1491.
  • DE WIT R, HERRSTEDT J, RAPOPORT B et al.: Addition of the oral NKI antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J. Cilia. Oncol (2003) 21:4105–4111.
  • DE WIT R, HERRSTEDT J, RAPOPORT B et al.: The oral NKI antagonist aprepitant given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of 2 randomized, placebo controlled Phase III trials. Eur: J. Cancer (2004) 40:403–410.
  • •Combined analysis of two randomised, double-blind, Phase III studies [87,88] showing that the antiemetic effect of aprepitant plus standard antiemetic therapy was maintained through six cycles of chemotherapy and superior to standard therapy alone.
  • TREMBLAY PB, KAISER R, SEZER O et al.: Variations in the 5-hydroxytryptamine Type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. Chit. Oncol (2003) 21:2147–2155.

Websites

  • http://www.mgipharma.com/ aloxi_pi.pdf.pdf Alwd (palonosetron hydrochloride). PI 2003.
  • http://www.fda.gov Merck background package for the FDA.
  • http://www.fda.gov FDA background information package for the panel members of the advisory committee.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.